Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea

S. C. Kim, T. Y. Ahn, H. K. Choi, N. G. Choi, T. G. Chung, W. S. Chung, T. K. Hwang, J. S. Hyun, G. W. Jung, C. I. Kim, Je-Jong Kim, S. W. Kim, C. H. Lee, K. S. Lee, W. H. Lee, K. S. Min, K. H. Moon, J. S. Paick, K. S. Park, N. C. ParkY. K. Park, J. K. Seo, K. K. Seo, J. S. Shin, Y. R. Yoon, W. C. Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. The erectile responses were evaluated using an erection assessment scale (score of 1-5). The dose that produced a maximal penile response of score 5 (full rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment group. In-clinic phase: 198 men (59.3%) had maximal penile responses of score 4 or 5. The rate of maximal responses was not related to patient age, etiology or duration of the ED. A total of 228 (68.3%) men progressed to home treatment. The overall level of comfort of the transurethral alprostadil was rated as uncomfortable or very uncomfortable in 12%. Home phase: During the two-month period of home treatment, 178 (78.1%) men had successful sexual intercourse at least once, and 78.2% of administrations (1976) resulted in successful intercourse. The main causes of drop-out were insufficient erectile response in 27 men (11.8%), adverse reactions (mostly penile or urethral pain) in 7 (3.1%) or both in 7 (3.1%). In conclusion, transurethral alprostadil could be a suitable treatment option for patients with ED regardless of age and etiology of ED. Efficacy in an Asian population (Korea) is comparable to that reported previously in Caucasians.

Original languageEnglish
Pages (from-to)97-101
Number of pages5
JournalInternational Journal of Impotence Research
Volume12
Issue number2
Publication statusPublished - 2000 Oct 2
Externally publishedYes

Fingerprint

Alprostadil
Erectile Dysfunction
Korea
Multicenter Studies
Group Homes
Therapeutics
Coitus
Pain
Population

Keywords

  • Efficacy
  • Erectile dysfunction
  • Safety
  • Transurethral alprostadil

ASJC Scopus subject areas

  • Urology

Cite this

Kim, S. C., Ahn, T. Y., Choi, H. K., Choi, N. G., Chung, T. G., Chung, W. S., ... Lee, W. C. (2000). Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea. International Journal of Impotence Research, 12(2), 97-101.

Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea. / Kim, S. C.; Ahn, T. Y.; Choi, H. K.; Choi, N. G.; Chung, T. G.; Chung, W. S.; Hwang, T. K.; Hyun, J. S.; Jung, G. W.; Kim, C. I.; Kim, Je-Jong; Kim, S. W.; Lee, C. H.; Lee, K. S.; Lee, W. H.; Min, K. S.; Moon, K. H.; Paick, J. S.; Park, K. S.; Park, N. C.; Park, Y. K.; Seo, J. K.; Seo, K. K.; Shin, J. S.; Yoon, Y. R.; Lee, W. C.

In: International Journal of Impotence Research, Vol. 12, No. 2, 02.10.2000, p. 97-101.

Research output: Contribution to journalArticle

Kim, SC, Ahn, TY, Choi, HK, Choi, NG, Chung, TG, Chung, WS, Hwang, TK, Hyun, JS, Jung, GW, Kim, CI, Kim, J-J, Kim, SW, Lee, CH, Lee, KS, Lee, WH, Min, KS, Moon, KH, Paick, JS, Park, KS, Park, NC, Park, YK, Seo, JK, Seo, KK, Shin, JS, Yoon, YR & Lee, WC 2000, 'Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea', International Journal of Impotence Research, vol. 12, no. 2, pp. 97-101.
Kim, S. C. ; Ahn, T. Y. ; Choi, H. K. ; Choi, N. G. ; Chung, T. G. ; Chung, W. S. ; Hwang, T. K. ; Hyun, J. S. ; Jung, G. W. ; Kim, C. I. ; Kim, Je-Jong ; Kim, S. W. ; Lee, C. H. ; Lee, K. S. ; Lee, W. H. ; Min, K. S. ; Moon, K. H. ; Paick, J. S. ; Park, K. S. ; Park, N. C. ; Park, Y. K. ; Seo, J. K. ; Seo, K. K. ; Shin, J. S. ; Yoon, Y. R. ; Lee, W. C. / Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea. In: International Journal of Impotence Research. 2000 ; Vol. 12, No. 2. pp. 97-101.
@article{90a34e3ab0474d1197163b05891ec9b5,
title = "Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea",
abstract = "A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30{\%} of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. The erectile responses were evaluated using an erection assessment scale (score of 1-5). The dose that produced a maximal penile response of score 5 (full rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment group. In-clinic phase: 198 men (59.3{\%}) had maximal penile responses of score 4 or 5. The rate of maximal responses was not related to patient age, etiology or duration of the ED. A total of 228 (68.3{\%}) men progressed to home treatment. The overall level of comfort of the transurethral alprostadil was rated as uncomfortable or very uncomfortable in 12{\%}. Home phase: During the two-month period of home treatment, 178 (78.1{\%}) men had successful sexual intercourse at least once, and 78.2{\%} of administrations (1976) resulted in successful intercourse. The main causes of drop-out were insufficient erectile response in 27 men (11.8{\%}), adverse reactions (mostly penile or urethral pain) in 7 (3.1{\%}) or both in 7 (3.1{\%}). In conclusion, transurethral alprostadil could be a suitable treatment option for patients with ED regardless of age and etiology of ED. Efficacy in an Asian population (Korea) is comparable to that reported previously in Caucasians.",
keywords = "Efficacy, Erectile dysfunction, Safety, Transurethral alprostadil",
author = "Kim, {S. C.} and Ahn, {T. Y.} and Choi, {H. K.} and Choi, {N. G.} and Chung, {T. G.} and Chung, {W. S.} and Hwang, {T. K.} and Hyun, {J. S.} and Jung, {G. W.} and Kim, {C. I.} and Je-Jong Kim and Kim, {S. W.} and Lee, {C. H.} and Lee, {K. S.} and Lee, {W. H.} and Min, {K. S.} and Moon, {K. H.} and Paick, {J. S.} and Park, {K. S.} and Park, {N. C.} and Park, {Y. K.} and Seo, {J. K.} and Seo, {K. K.} and Shin, {J. S.} and Yoon, {Y. R.} and Lee, {W. C.}",
year = "2000",
month = "10",
day = "2",
language = "English",
volume = "12",
pages = "97--101",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea

AU - Kim, S. C.

AU - Ahn, T. Y.

AU - Choi, H. K.

AU - Choi, N. G.

AU - Chung, T. G.

AU - Chung, W. S.

AU - Hwang, T. K.

AU - Hyun, J. S.

AU - Jung, G. W.

AU - Kim, C. I.

AU - Kim, Je-Jong

AU - Kim, S. W.

AU - Lee, C. H.

AU - Lee, K. S.

AU - Lee, W. H.

AU - Min, K. S.

AU - Moon, K. H.

AU - Paick, J. S.

AU - Park, K. S.

AU - Park, N. C.

AU - Park, Y. K.

AU - Seo, J. K.

AU - Seo, K. K.

AU - Shin, J. S.

AU - Yoon, Y. R.

AU - Lee, W. C.

PY - 2000/10/2

Y1 - 2000/10/2

N2 - A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. The erectile responses were evaluated using an erection assessment scale (score of 1-5). The dose that produced a maximal penile response of score 5 (full rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment group. In-clinic phase: 198 men (59.3%) had maximal penile responses of score 4 or 5. The rate of maximal responses was not related to patient age, etiology or duration of the ED. A total of 228 (68.3%) men progressed to home treatment. The overall level of comfort of the transurethral alprostadil was rated as uncomfortable or very uncomfortable in 12%. Home phase: During the two-month period of home treatment, 178 (78.1%) men had successful sexual intercourse at least once, and 78.2% of administrations (1976) resulted in successful intercourse. The main causes of drop-out were insufficient erectile response in 27 men (11.8%), adverse reactions (mostly penile or urethral pain) in 7 (3.1%) or both in 7 (3.1%). In conclusion, transurethral alprostadil could be a suitable treatment option for patients with ED regardless of age and etiology of ED. Efficacy in an Asian population (Korea) is comparable to that reported previously in Caucasians.

AB - A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. The erectile responses were evaluated using an erection assessment scale (score of 1-5). The dose that produced a maximal penile response of score 5 (full rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment group. In-clinic phase: 198 men (59.3%) had maximal penile responses of score 4 or 5. The rate of maximal responses was not related to patient age, etiology or duration of the ED. A total of 228 (68.3%) men progressed to home treatment. The overall level of comfort of the transurethral alprostadil was rated as uncomfortable or very uncomfortable in 12%. Home phase: During the two-month period of home treatment, 178 (78.1%) men had successful sexual intercourse at least once, and 78.2% of administrations (1976) resulted in successful intercourse. The main causes of drop-out were insufficient erectile response in 27 men (11.8%), adverse reactions (mostly penile or urethral pain) in 7 (3.1%) or both in 7 (3.1%). In conclusion, transurethral alprostadil could be a suitable treatment option for patients with ED regardless of age and etiology of ED. Efficacy in an Asian population (Korea) is comparable to that reported previously in Caucasians.

KW - Efficacy

KW - Erectile dysfunction

KW - Safety

KW - Transurethral alprostadil

UR - http://www.scopus.com/inward/record.url?scp=0033835005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033835005&partnerID=8YFLogxK

M3 - Article

C2 - 11052635

AN - SCOPUS:0033835005

VL - 12

SP - 97

EP - 101

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 2

ER -